GLP-1 agonists like Ozempic lower cancer risks in study

ScienceAlert July 8, 2024, 04:00 AM UTC

Summary: A study in JAMA suggests GLP-1 agonists, including Ozempic, reduce the risk of certain obesity-related cancers. Patients with Type 2 diabetes on these drugs had significantly lower risks of 10 out of 13 cancers studied. GLP-1 agonists like Ozempic may break the link between obesity and cancer. This could lead to more doctors prescribing these drugs over insulin for diabetes treatment.

Full article

Article metrics
Significance5.5
Scale7.0
Magnitude8.0
Novelty6.0
Actionability5.0
Immediacy7.0
Positivity8.0
Probability9.0
Credibility7.8

Timeline:

  1. [2.5]
    Semaglutide may pose risk of vision loss: Study urges caution (Business Standard)
    1d
    Source
  2. [4.7]
    Ozempic improves heart and kidney health for diabetes patients (Sydney Morning Herald)
    2d
    Source
  3. [4.9]
    Semaglutide (Ozempic) may reduce dementia risk and nicotine cravings (Neuroscience News)
    3d
    Source
  4. [3.2]
    Ozempic linked to lower dementia risk, nicotine use in study (The Globe and Mail)
    3d
    Source
  5. [3.2]
    Ozempic linked to lower dementia risk, nicotine use - study (The Straits Times)
    3d
    Source
  6. [3.9]
    Antidiabetic drugs linked to lower dementia risk in T2DM (News-Medical.Net)
    3d
    Source
  7. [4.0]
    Ozempic linked to lower dementia rate in Oxford study (BNN Bloomberg)
    3d
    Source
  8. [3.5]
    Ozempic and similar drugs may lower cancer risks (Forbes Australia)
    3d
    Source
  9. [3.3]
    GLP-1 agonists lower dementia risk for diabetes patients (PsyPost)
    3d
    Source
  10. [3.9]
    Weight-loss jabs lower cancer risk compared to insulin - study (The Conversation)
    4d
    Source
  11. [4.7]
    GLP-1 agonists reduce cancer risk in type 2 diabetes (Inside Precision Medicine)
    5d
    Source
  12. [3.4]
    GLP-1s reduce cancer risk in type 2 diabetes patients (PMLiVE)
    5d
    Source
  13. [3.9]
    GLP-1 drugs linked to lower cancer risks in diabetes patients (Ars Technica)
    6d
    Source
  14. [3.5]
    Semaglutide linked to rare eye disease causing vision loss (ScienceAlert)
    6d
    Source
  15. [2.2]
    Semaglutide linked to higher risk of NAION in study (The Express Tribune)
    7d
    Source
  16. [2.5]
    Semaglutide (Ozempic) linked to increased risk of blindness (Insight)
    7d
    Source
  17. [5.3]
    GLP-1 meds like Ozempic, Wegovy may lower cancer risk (CTV News)
    8d

  18. [4.4]
    GLP-1 diabetes drugs reduce cancer risk, study finds (The Manila Times)
    9d
    Source
  19. [5.0]
    GLP-1 medications may lower risk of certain cancers (CNN)
    9d

  20. [2.2]
    GLP-1s lower risk of 10 obesity-related cancers in diabetes (Medpage Today)
    10d
    Source
  21. [5.2]
    GLP-1 drugs like Ozempic may reduce cancer risk (Quartz)
    10d

  22. [5.1]
    GLP-1 treatments reduce cancer risk in diabetes patients (GMA News Online)
    10d

  23. [5.1]
    GLP-1 drugs reduce cancer risks for diabetes patients (Finimize)
    10d

  24. [1.3]
    Weight loss drugs linked to rare eye condition risk (India TV News)
    10d
    Source
  25. [2.9]
    Weight-loss drugs may increase risk of rare blindness (Firstpost)
    11d
    Source
  26. [3.2]
    Novo Nordisk weight loss drugs linked to rare eye condition (CNBC)
    11d
    Source
  27. [3.3]
    Ozempic linked to rare blindness cases in study (Business Insider)
    12d
    Source
  28. [3.2]
    Wegovy, Ozempic linked to sight-threatening eye disorder in study (GMA News Online)
    12d
    Source
  29. [3.4]
    Weight loss and diabetes drugs linked to rare blindness risk (CNN)
    12d
    Source
  30. [3.2]
    Weight-loss jabs linked to potential blindness risk in study (The Guardian)
    12d
    Source